People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharmaceuticals, Biotechnology, Other, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vigil Neuroscience, Inc. | — | Pharmaceuticals | Series C | $215.0M | $1.3B | 2020 |
| G1 Therapeutics, Inc. | — | Biotechnology | Series C | $134.9M | $2.0B | 2013 |
| PhaseBio Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $102.1M | $912.3M | 2009 |
| StrideBio, Inc. | — | Biotechnology | Series C | $57.7M | $1.5B | 2018 |
| Lysosomal Therapeutics, Inc. | — | Biotechnology | Series B | $38.0M | $39.7M | 2015 |
| ORIG3N, Inc. | — | Other | Series B | $32.8M | $434.9M | 2018 |
| Artizan Biosciences, Inc. | — | Biotechnology | Series B | $30.1M | $6.0M | 2025 |
| GeneCentric Therapeutics, Inc. | — | Biotechnology | Series A | $21.6M | $6.7M | 2020 |
| Pathfinder Therapeutics, Inc. | — | Other Health Care | Series A | $12.6M | $25.1M | 2012 |
| CancerGuide Diagnostics, Inc. | — | Biotechnology | Seed | $4.7M | $122.1M | 2010 |
Clay Thorp at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Clay Thorp on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Booth | 2 | 12 |
| Shaan Gandhi | 2 | 4 |
| Michael K. Gutch | 2 | 2 |
| Myla Lai-Goldman | 2 | 2 |
| Thomas K Laundon | 2 | 2 |
| Garheng Kong | 1 | 16 |
| David King | 1 | 16 |
| Richard Smith | 1 | 11 |
| Michael Martin | 1 | 11 |
| Byron Smith | 1 | 8 |
| Richard Molloy | 1 | 7 |
| Justin Klein | 1 | 6 |
| Tyrell Rivers | 1 | 6 |
| Robert Hughes | 1 | 6 |
| Christy Shaffer | 1 | 6 |
| Daniel Geffken | 1 | 6 |
| Robert Carpenter | 1 | 5 |
| Linda Tufts | 1 | 5 |
| Elona Baum | 1 | 5 |
| Arnold Levine | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.